Accessibility Menu
 
Viridian Therapeutics logo

Viridian Therapeutics

(NASDAQ) VRDN

Current Price$16.84
Market Cap$1.73B
Since IPO (2017)-91%
5 Year-3%
1 Year+33%
1 Month+13%

Viridian Therapeutics Financials at a Glance

Market Cap

$1.73B

Revenue (TTM)

$70.92M

Net Income (TTM)

$360.59M

EPS (TTM)

$-3.76

P/E Ratio

-4.47

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$16.84

Volume

1,614,544.079

Open

$17.26

Previous Close

$16.82

Daily Range

$16.71 - $17.38

52-Week Range

$12.51 - $34.29

VRDN: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viridian Therapeutics

Industry

Biotechnology

Employees

252

CEO

Stephen Frank Mahoney, MBA

Headquarters

Waltham, MA 02453, US

VRDN Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-5%

Net Income Margin

-5%

Return on Equity

-55%

Return on Capital

-52%

Return on Assets

-46%

Earnings Yield

-22.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.73B

Shares Outstanding

103.08M

Volume

1.61M

Avg. Volume

2.73M

Financials (TTM)

Gross Profit

$70.85M

Operating Income

$363.39M

EBITDA

$337.19M

Operating Cash Flow

$276.39M

Capital Expenditure

$495.00K

Free Cash Flow

$276.89M

Cash & ST Invst.

$874.65M

Total Debt

$50.69M

Viridian Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$141.00K

+95.8%

Gross Profit

$20.00K

-72.2%

Gross Margin

14.18%

N/A

Market Cap

$1.73B

N/A

Market Cap/Employee

$12.12M

N/A

Employees

143

N/A

Net Income

$104.90M

-20.7%

EBITDA

$116.17M

-34.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$711.01M

+15.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$50.44M

+143.8%

Short Term Debt

$738.00K

+37.7%

Return on Assets

-45.70%

N/A

Return on Invested Capital

-52.32%

N/A

Free Cash Flow

$119.68M

-29.0%

Operating Cash Flow

$119.65M

-29.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QUREuniQure N.V.
$27.05-2.52%
GLPGGalapagos N.V.
$27.09-1.46%
OCULOcular Therapeutix, Inc.
$9.16-3.58%
CLDXCelldex Therapeutics, Inc.
$31.34-3.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$10.62-0.05%
INTCIntel
$108.77-0.06%
NOKNokia
$13.95-0.04%
FFord Motor Company
$13.40-0.07%

Questions About VRDN

What is the current price of Viridian Therapeutics?

Viridian Therapeutics is trading at $16.82 per share.

What is the 52-week range for Viridian Therapeutics?

Over the past 52 weeks, Viridian Therapeutics has traded between $12.51 and $34.29.

How much debt does Viridian Therapeutics have?

As of the most recent reporting period, Viridian Therapeutics reported total debt of $51.17M.

How much cash does Viridian Therapeutics have on hand?

Viridian Therapeutics reported $176.35M in cash and cash equivalents in its most recent financial results.

What is Viridian Therapeutics’s dividend yield?

Viridian Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.